Azithromycin,Erythromycin and Cloxacillin in the Treatment of Infections of Skin and Associated Soft Tissues

Abstract

Azithromycin (total dose 1.5 g) given orally in five or six doses over 5 days was compared with erythromycin and cloxacillin both given orally as 500 mg four times daily for 7 days in two multicentre studies of patients with skin and associated soft-tissue infections. Azithromycin eradicated baseline pathogen(s), mainly Staphylococcus aureus, in 89% compared with in 78%, of erythromycin-treated patients (P = 0.501) and in 78% compared with in 59% of cloxacillin-treated patients (P = 0.421). No statistically significant difference in clinical cure was reported between azithromycin (74%) and erythromycin (75%, P = 1.00) and between azithromycin (60%) and cloxacillin (47%, P = 0.301) treatment groups. The side-effects reported for azithromycin were mainly mild or moderate gastrointestinal complaints and there were no major abnormalities in laboratory parameters. It is concluded that azith-romycin was as effective as, but better tolerated than, either erythromycin or cloxacillin and short-course therapy may improve patient compliance.

Keywords

Azithromycin erythromycin cloxacillin antibacterial agents skin infections soft-tissue infections

Get full access to this article

View all access options for this article.

References

Retsema

Girard

Schelkly

: Spectrum and mode of action of azithromycin (CP 62,993), a new 15-membered-ring macrolide with improved potency against Gram-negative organisms. Antimicrob Agents Chemother 1987; 31: 1939–1947.

Girard

Cinochowski

Faiella

: Effectiveness of azithromycin in eradicating streptococcal pathogens from localized infections [abstract], 6th International Congress on Infectious Diseases, Montreal, 1990.

Gladue

Snider

: Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob Agents Chemother 1990; 34: 1056–1060.

Gladue

Bright

Isaacson

: In vitro and in vivo uptake of azithromycin (CP 62, 993) by phagocytic cells; possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989; 33: 277–282.

Foulds

Shepard

Johnson

: The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25 (suppl A): 73–82.

Dette

: Vergleich der gewebegangigkeit von erythromycin. Infection 1979; 7: 129–145.

Girard

Retsema

: Correlation of the extravascular pharmacokinetics of azithromycin with in vivo efficacy in models of localised infections. J Antimicrob Chemother 1990; 25 (suppl A): 61–71.

Cockburn

Gibberd

Reid

: Determinants of non-compliance with short-term antibiotic regimens. Br Med J 1987; 295: 814–818.

Cacciatore

: Controlled multicenter clinical comparison between two cefatrizine administration schedules: a contribution to improvement of compliance in clinical non-hospital use of antibiotics. Clin Ther 1988; 10: 266–274.